Annexin Pharmaceuticals AB (OSTO:ANNX) 3-1 Month Momentum %: -9.04% (As of Aug. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:ANNX Annexin Pharmaceuticals AB OSTO:ANNX
19 GF Score
Price kr13.20
! 1 Warning Sign
View Full Analysis

What is Annexin Pharmaceuticals AB 3-1 Month Momentum %?

Annexin Pharmaceuticals AB OSTO:ANNX +3.12% 19 3-1 Month Momentum % is -9.04% as of Aug. 22, 2026. GuruFocus rates OSTO:ANNX with a GF Score™ of 19/100. The stock has 1 warning sign investors should review. Among 1,386 Biotechnology companies, Annexin Pharmaceuticals AB ranks worse than 57.36% on this metric.

3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-22), Annexin Pharmaceuticals AB's 3-1 Month Momentum % is -9.04%.

The industry rank for Annexin Pharmaceuticals AB's 3-1 Month Momentum % or its related term are showing as below:

OSTO:ANNX's 3-1 Month Momentum % is ranked worse than
57.36% of 1386 companies
in the Biotechnology industry
Industry Median: -7.01 vs OSTO:ANNX: -9.04

Annexin Pharmaceuticals AB  (OSTO:ANNX) 3-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Annexin Pharmaceuticals AB 3-1 Month Momentum % Related Terms

OSTO:ANNX vs VRTX, REGN, RVMD: 3-1 Month Momentum % Comparison

For the Biotechnology subindustry, Annexin Pharmaceuticals AB's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Annexin Pharmaceuticals AB 3-1 Month Momentum % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Annexin Pharmaceuticals AB's 3-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Annexin Pharmaceuticals AB's 3-1 Month Momentum % falls into.


OSTO:ANNX
19GF Score
Annexin Pharmaceuticals AB OSTO:ANNX
3-1 Month Momentum % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Annexin Pharmaceuticals AB  (OSTO:ANNX) 3-1 Month Momentum % Calculation

3-1 Month Momentum % is calculated as following:

3-1 Month Momentum %=( Price 1-month ago / Price 3-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 3-1 Month Momentum % →
What does a 3-1 Month Momentum % of -9.04% mean?
Annexin Pharmaceuticals AB (OSTO:ANNX) has a 3-1 Month Momentum % of -9.04% as of Aug. 22, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Annexin Pharmaceuticals AB and its competitors. According to the industry distribution chart, Annexin Pharmaceuticals AB ranks #795 out of 1386 companies in the Biotechnology industry, placing it in the top 57.4%.
Is Annexin Pharmaceuticals AB's 3-1 Month Momentum % too high?
Annexin Pharmaceuticals AB's current 3-1 Month Momentum % is -9.04%. Based on the distribution chart, Annexin Pharmaceuticals AB ranks #795 out of 1386 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Annexin Pharmaceuticals AB has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Annexin Pharmaceuticals AB's 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Annexin Pharmaceuticals AB ranks #795 out of 1386 companies for 3-1 Month Momentum %. This places Annexin Pharmaceuticals AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Annexin Pharmaceuticals AB and its competitors. Annexin Pharmaceuticals AB's current 3-1 Month Momentum % is -9.04%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Annexin Pharmaceuticals AB stock overvalued right now?
Annexin Pharmaceuticals AB (OSTO:ANNX) has a current 3-1 Month Momentum % of -9.04%. The current 3-1 Month Momentum % is -9.04%. Annexin Pharmaceuticals AB's overall GF Score™ is 19/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Annexin Pharmaceuticals AB (OSTO:ANNX), the current 3-1 Month Momentum % is -9.04% as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Annexin Pharmaceuticals AB Business Description

Other Exchanges Q910:Germany
Address Kammakargatan 48, Stockholm, SWE, 111 60
Annexin Pharmaceuticals AB is a biotechnology company. It is developing biological drug candidate ANXV, a recombinant human protein Annexin A5 for treatment of various cardiovascular diseases. The company also focuses on development of ANXV for the treatment of retinal vein occlusion.
19GF Score

Get the complete analysis for OSTO:ANNX

3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr13.20
Price